The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma

被引:52
作者
Andrade, Valeria Cristina da Costa
Parise, Orlando, Jr.
Hors, Cora Pereira
Martins, Poliana Cristina de Melo
Silva, Alexandre Pacheco
Garicochea, Bernardo
机构
[1] Pontificia Univ Catolica Rio Grande do Sul, Ctr Clin, Hosp Sao Lucas, BR-90630010 Porto Alegre, RS, Brazil
[2] Sirio Libanes Hosp, Sao Paulo, Brazil
[3] Pontificia Univ Catolica Rio Grande Do Sul, Med Sch, Oncol Dept, Porto Alegre, RS, Brazil
[4] Lab Mol Genet, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
FGFR4; head and neck squamous cell carcinoma; prognosis; polymorphism;
D O I
10.1016/j.yexmp.2006.05.003
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: The increased expression of the fibroblast growth factor receptor 4 (FGFR4) has been identified in many human cancers. Recently, a single nucleotide polymorphism changing the sense codon 388 from glycine to arginine was identified in the FGFR4 gene. The FGFR4 Arg(388) allele was found to be associated with a poor prognosis for positive node breast cancer, high-grade soft-tissue sarcoma, colon carcinoma, and head and neck squamous cell carcinoma (HNSCC). Methods: We decided to verify the impact of the FGFR4 Arg(388) allele on survival as well as its association with histoclinical data in 75 cases of HNSCC. The FGFR4 Arg(388) allele was detected by PCR-RFLP and DNA sequencing. Results: The FGFR4 Arg(388) allele was detected in 42.5% of the tumors (37% heterozygous Gly/Arg and 5.5% homozygous Arg/Arg). The presence of at least one Arg allele was significantly correlated with reduced overall survival after 24 months of follow-up. The cases involving the Arg allele presented an increased mortality risk of 2.2 if compared to the non-carrier cases. Conclusion: The FGFR4 Arg 388 allele is associated with a shortened survival. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:53 / 57
页数:5
相关论文
共 21 条
  • [1] Bange J, 2002, CANCER RES, V62, P840
  • [2] FGF signals for cell proliferation and migration through different pathways
    Boilly, B
    Vercoutter-Edouart, AS
    Hondermarck, H
    Nurcombe, V
    Le Bourhis, X
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2000, 11 (04) : 295 - 302
  • [3] Braakhuis BJM, 2003, CANCER RES, V63, P1727
  • [4] Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
    Cappellen, D
    De Oliveira, C
    Ricol, D
    de Medina, SGD
    Bourdin, J
    Sastre-Garau, X
    Chopin, D
    Thiery, JP
    Radvanyi, F
    [J]. NATURE GENETICS, 1999, 23 (01) : 18 - 20
  • [5] Multitasking in tumor progression - Signaling functions of cell adhesion molecules
    Cavallaro, U
    Christofori, G
    [J]. GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE: MOLECULAR AND CELL BIOLOGICAL ASPECTS, 2004, 1014 : 58 - 66
  • [6] Gervasio O L, 2001, Braz Dent J, V12, P57
  • [7] Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer
    Gowardhan, B
    Douglas, DA
    Mathers, ME
    McKie, AB
    McCracken, SRC
    Robson, CN
    Leung, HY
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (02) : 320 - 327
  • [8] Hasina R, 2003, CANCER RES, V63, P555
  • [9] AMPLIFICATION OF FGFR4 GENE IN HUMAN BREAST AND GYNECOLOGICAL CANCERS
    JAAKKOLA, S
    SALMIKANGAS, P
    NYLUND, S
    PARTANEN, J
    ARMSTRONG, E
    PYRHONEN, S
    LEHTOVIRTA, P
    NEVANLINNA, H
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1993, 54 (03) : 378 - 382
  • [10] G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis
    Jézéquel, P
    Campion, L
    Joalland, MP
    Millour, M
    Dravet, F
    Classe, JM
    Delecroix, V
    Deporte, R
    Fumoleau, P
    Ricolleau, G
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 189 - 193